Meu SciELO
Serviços customizadosServiços Personalizados
Journal
Artigo
Espanhol (pdf)
Artigo em XML
Referências do artigo
Tradução automática
Enviar este artigo por emailIndicadores
Citado por SciELO 
Acessos
Links relacionados
Citado por Google 
Similares em
SciELO 
Similares em Google
Compartilhar
Permalink
Farmacia Hospitalaria
versão On-line ISSN 2171-8695versão impressa ISSN 1130-6343
Resumo
FERNANDEZ-CANABATE, Eva e FERNANDEZ-CANABATE, Sonia. Intravitreal rituximab for the treatment of intraocular relapse of non-Hodgkin’s lymphoma. Farm Hosp. [online]. 2018, vol.42, n.1, pp.20-21. ISSN 2171-8695. https://dx.doi.org/10.7399/fh.10830.
Clinical case:
A 58-year-old woman with intraocular relapse of a diffuse large B cell lymphoma. Weekly intravitreal rituximab (1 mg/0.1 ml) for 4 weeks were administered. 12 months after the last intravitreal rituximab dose, signs and symptoms of lymphomas or adverse reactions associated with intravitreal Rituximab administration were not observed.
Discussion:
Intravitreal rituximab is an effective and safe treatment of intravitreal lymphoma, by inducing complete remission; it could be a good alternative to other therapeutic options with greater number of serious complications.
Palavras-chave : Rituximab; Primary colon lymphoma; Diffuse large B cell lymphoma; Vitreoretinal lymphoma; Intravitreal injection; Non Hodgkin’s lymphoma.
